Cargando…
Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm
INTRODUCTION: It is unclear whether adding basal insulin or enhancing incretin signaling with a glucagon-like peptide-1 receptor agonist (GLP-1RA) is more effective as an up-titration strategy after dipeptidyl peptidase-4 inhibitor (DPP-4i)-based oral antidiabetic drug (OAD) therapy. GLP-1RAs can be...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167274/ https://www.ncbi.nlm.nih.gov/pubmed/30121725 http://dx.doi.org/10.1007/s13300-018-0486-1 |
_version_ | 1783360159466127360 |
---|---|
author | Miyagi, Masahiko Uchino, Hiroshi Kumashiro, Naoki Higa, Mariko Shin, Koki Sasamoto, Makiko Kitazato, Hiroji Tamaki, Motoyuki Matsuhisa, Munehide Hirose, Takahisa |
author_facet | Miyagi, Masahiko Uchino, Hiroshi Kumashiro, Naoki Higa, Mariko Shin, Koki Sasamoto, Makiko Kitazato, Hiroji Tamaki, Motoyuki Matsuhisa, Munehide Hirose, Takahisa |
author_sort | Miyagi, Masahiko |
collection | PubMed |
description | INTRODUCTION: It is unclear whether adding basal insulin or enhancing incretin signaling with a glucagon-like peptide-1 receptor agonist (GLP-1RA) is more effective as an up-titration strategy after dipeptidyl peptidase-4 inhibitor (DPP-4i)-based oral antidiabetic drug (OAD) therapy. GLP-1RAs can be injected without dose adjustment, unlike basal insulin. Our objective was to examine the efficacy of changing patients inadequately controlled with oral DPP-4i-based OAD therapy to injectable GLP-1RA and discontinuing the DPP4i versus adding basal insulin glargine (IGlar) with the continuation of the oral DPP4i. METHODS: Sixty patients with type 2 diabetes (T2DM) and glycated hemoglobin (HbA1c) between 7.0% and 10.0% on DPP-4i-based OAD therapy were randomized to either adding IGlar and remaining on the DPP-4i or liraglutide and discontinuing the DPP-4i for 24 weeks. Patients in the IGlar group started with 0.1 unit/kg and were titrated according to the algorithm. In the liraglutide group, the DPP-4i was replaced with liraglutide 0.9 mg/day, the maximum dose in Japan. We evaluated HbA1c, glycated albumin (GA), and anthropometrics. RESULTS: HbA1c was significantly lower at week 24 (− 1.0 ± 0.9% in the IGlar group and − 0.6 ± 0.8% in the liraglutide group), but the difference between groups was not significant. Changes in GA were similar (− 2.9 ± 3.2% vs. − 2.6 ± 3.2%) in both groups. Body weight (BW) was significantly lower only in the liraglutide group (+ 0.5 ± 2.6 kg vs. − 2.2 ± 2.0 kg). The rate of minor hypoglycemic episodes was similar for both groups. CONCLUSION: For poorly controlled T2DM on DPP-4i-based OAD therapy, switching to single-dose liraglutide to enhance incretin signaling is as effective as dose-titrated basal IGlar, but significant BW reduction was only seen in the liraglutide group. These results suggest that enhancing incretin signaling with a single-dose injectable GLP-1 RA might be an alternative to dose-titrated basal insulin therapy in patients with T2DM poorly controlled with DPP-4i-based OAD therapy. These findings should be confirmed in a longer and larger trial. TRIAL REGISTRATION: Trial Registry (UMIN-CTR) as UMIN000012224. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13300-018-0486-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6167274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-61672742018-10-08 Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm Miyagi, Masahiko Uchino, Hiroshi Kumashiro, Naoki Higa, Mariko Shin, Koki Sasamoto, Makiko Kitazato, Hiroji Tamaki, Motoyuki Matsuhisa, Munehide Hirose, Takahisa Diabetes Ther Original Research INTRODUCTION: It is unclear whether adding basal insulin or enhancing incretin signaling with a glucagon-like peptide-1 receptor agonist (GLP-1RA) is more effective as an up-titration strategy after dipeptidyl peptidase-4 inhibitor (DPP-4i)-based oral antidiabetic drug (OAD) therapy. GLP-1RAs can be injected without dose adjustment, unlike basal insulin. Our objective was to examine the efficacy of changing patients inadequately controlled with oral DPP-4i-based OAD therapy to injectable GLP-1RA and discontinuing the DPP4i versus adding basal insulin glargine (IGlar) with the continuation of the oral DPP4i. METHODS: Sixty patients with type 2 diabetes (T2DM) and glycated hemoglobin (HbA1c) between 7.0% and 10.0% on DPP-4i-based OAD therapy were randomized to either adding IGlar and remaining on the DPP-4i or liraglutide and discontinuing the DPP-4i for 24 weeks. Patients in the IGlar group started with 0.1 unit/kg and were titrated according to the algorithm. In the liraglutide group, the DPP-4i was replaced with liraglutide 0.9 mg/day, the maximum dose in Japan. We evaluated HbA1c, glycated albumin (GA), and anthropometrics. RESULTS: HbA1c was significantly lower at week 24 (− 1.0 ± 0.9% in the IGlar group and − 0.6 ± 0.8% in the liraglutide group), but the difference between groups was not significant. Changes in GA were similar (− 2.9 ± 3.2% vs. − 2.6 ± 3.2%) in both groups. Body weight (BW) was significantly lower only in the liraglutide group (+ 0.5 ± 2.6 kg vs. − 2.2 ± 2.0 kg). The rate of minor hypoglycemic episodes was similar for both groups. CONCLUSION: For poorly controlled T2DM on DPP-4i-based OAD therapy, switching to single-dose liraglutide to enhance incretin signaling is as effective as dose-titrated basal IGlar, but significant BW reduction was only seen in the liraglutide group. These results suggest that enhancing incretin signaling with a single-dose injectable GLP-1 RA might be an alternative to dose-titrated basal insulin therapy in patients with T2DM poorly controlled with DPP-4i-based OAD therapy. These findings should be confirmed in a longer and larger trial. TRIAL REGISTRATION: Trial Registry (UMIN-CTR) as UMIN000012224. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13300-018-0486-1) contains supplementary material, which is available to authorized users. Springer Healthcare 2018-08-18 2018-10 /pmc/articles/PMC6167274/ /pubmed/30121725 http://dx.doi.org/10.1007/s13300-018-0486-1 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Miyagi, Masahiko Uchino, Hiroshi Kumashiro, Naoki Higa, Mariko Shin, Koki Sasamoto, Makiko Kitazato, Hiroji Tamaki, Motoyuki Matsuhisa, Munehide Hirose, Takahisa Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm |
title | Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm |
title_full | Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm |
title_fullStr | Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm |
title_full_unstemmed | Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm |
title_short | Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm |
title_sort | up-titration strategy after dpp-4 inhibitor-based oral therapy for type 2 diabetes: a randomized controlled trial shifting to a single-dose glp-1 enhancer versus adding a variable basal insulin algorithm |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167274/ https://www.ncbi.nlm.nih.gov/pubmed/30121725 http://dx.doi.org/10.1007/s13300-018-0486-1 |
work_keys_str_mv | AT miyagimasahiko uptitrationstrategyafterdpp4inhibitorbasedoraltherapyfortype2diabetesarandomizedcontrolledtrialshiftingtoasingledoseglp1enhancerversusaddingavariablebasalinsulinalgorithm AT uchinohiroshi uptitrationstrategyafterdpp4inhibitorbasedoraltherapyfortype2diabetesarandomizedcontrolledtrialshiftingtoasingledoseglp1enhancerversusaddingavariablebasalinsulinalgorithm AT kumashironaoki uptitrationstrategyafterdpp4inhibitorbasedoraltherapyfortype2diabetesarandomizedcontrolledtrialshiftingtoasingledoseglp1enhancerversusaddingavariablebasalinsulinalgorithm AT higamariko uptitrationstrategyafterdpp4inhibitorbasedoraltherapyfortype2diabetesarandomizedcontrolledtrialshiftingtoasingledoseglp1enhancerversusaddingavariablebasalinsulinalgorithm AT shinkoki uptitrationstrategyafterdpp4inhibitorbasedoraltherapyfortype2diabetesarandomizedcontrolledtrialshiftingtoasingledoseglp1enhancerversusaddingavariablebasalinsulinalgorithm AT sasamotomakiko uptitrationstrategyafterdpp4inhibitorbasedoraltherapyfortype2diabetesarandomizedcontrolledtrialshiftingtoasingledoseglp1enhancerversusaddingavariablebasalinsulinalgorithm AT kitazatohiroji uptitrationstrategyafterdpp4inhibitorbasedoraltherapyfortype2diabetesarandomizedcontrolledtrialshiftingtoasingledoseglp1enhancerversusaddingavariablebasalinsulinalgorithm AT tamakimotoyuki uptitrationstrategyafterdpp4inhibitorbasedoraltherapyfortype2diabetesarandomizedcontrolledtrialshiftingtoasingledoseglp1enhancerversusaddingavariablebasalinsulinalgorithm AT matsuhisamunehide uptitrationstrategyafterdpp4inhibitorbasedoraltherapyfortype2diabetesarandomizedcontrolledtrialshiftingtoasingledoseglp1enhancerversusaddingavariablebasalinsulinalgorithm AT hirosetakahisa uptitrationstrategyafterdpp4inhibitorbasedoraltherapyfortype2diabetesarandomizedcontrolledtrialshiftingtoasingledoseglp1enhancerversusaddingavariablebasalinsulinalgorithm |